0.32
-0.0124(-3.70%)
Currency In USD
| Previous Close | 0.33 |
| Open | 0.32 |
| Day High | 0.34 |
| Day Low | 0.31 |
| 52-Week High | 2 |
| 52-Week Low | 0.22 |
| Volume | 550,258 |
| Average Volume | 2.01M |
| Market Cap | 13.52M |
| PE | -0.67 |
| EPS | -0.48 |
| Moving Average 50 Days | 0.3 |
| Moving Average 200 Days | 0.6 |
| Change | -0.01 |
If you invested $1000 in FibroBiologics, Inc. Common Stock (FBLG) since IPO date, it would be worth $18.43 as of January 21, 2026 at a share price of $0.323. Whereas If you bought $1000 worth of FibroBiologics, Inc. Common Stock (FBLG) shares 1 year ago, it would be worth $183.24 as of January 21, 2026 at a share price of $0.323.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
FibroBiologics to Present at the DealFlow Discovery Conference
GlobeNewswire Inc.
12 hours ago
HOUSTON, Jan. 20, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for c
FibroBiologics CEO Issues Letter to Shareholders
GlobeNewswire Inc.
Jan 07, 2026 1:30 PM GMT
HOUSTON, Jan. 07, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for c
FibroBiologics to Present at 9th Annual BFC Global Healthcare Business Development and Investment Conference
GlobeNewswire Inc.
Jan 06, 2026 1:30 PM GMT
HOUSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and pote